Hongri Pharmaceutical released its 2026 interim report. First-half operating revenue was 2.19 billion yuan, down 21.7% year on year, and net profit attributable to the parent was 78.09 million yuan, down 0.7% year on year. Second-quarter operating revenue was 1.06 billion yuan, down 24.6% year on year, and net profit attributable to the parent was 12.37 million yuan, down 32.4% year on year. First-half net profit attributable to the parent after deducting non-recurring items was 80.72 million yuan, up 16.7% year on year, and net operating cash flow was 358 million yuan, down 6.6% year on year. As of the end of the second quarter, total assets were 10.328 billion yuan, down 0.6% from the end of the previous year, and net assets attributable to the parent were 8.559 billion yuan, up 0.5% from the end of the previous year.
Tianjin Chase Sun Pharmaceutical Co LtdFirst-half net profit attributable to parent fell 0.7% year on year, with revenue down 21.7%.
